【摘要】：目的系統(tǒng)評價燈盞生脈膠囊佐治缺血性腦卒中的臨床療效及其二級預防作用。方法計算機檢索Pubmed、EMbase、Cochrane Library和CNKI、CBM、VIP、Wanfang Data,檢索時限為建庫至2016年2月,同時手工檢索相關雜志和網(wǎng)頁搜索谷歌學術,納入關于燈盞生脈膠囊佐治缺血性腦卒中的隨機對照試驗。由2名研究者獨立地按照納入和排除標準篩選文獻、提取相關數(shù)據(jù)并進行質(zhì)量評價,采用Rev Man5.3對結(jié)局指標進行meta分析。結(jié)果共納入文獻18篇,患者4 416例。Meta分析結(jié)果顯示,與對照組相比,試驗組能降低腦卒中復發(fā)率[RR=0.53,95%CI(0.39,0.71),P0.000 1]和病死率[RR=0.28,95%CI(0.11,0.68),P0.005],且在臨床療效[RR=1.22,95%CI(1.15,1.29),P0.000 01]及日常生活能力[MD=9.19,95%CI(3.41,14.98),P=0.002]上要優(yōu)于對照組;在殘障功能改善程度[MD=?0.04,95%CI(?0.16,0.07),P=0.47][RR=1.11,95%CI(0.89,1.40),P=0.35]和不良反應發(fā)生率[RR=0.68,95%CI(0.34,1.37),P=0.29]上2組間無明顯差異。結(jié)論燈盞生脈膠囊佐治缺血性腦卒中與常規(guī)治療相比能夠降低腦卒中復發(fā)率和病死率,且在臨床療效和日常生活能力上要優(yōu)于常規(guī)治療。在殘障功能改善程度上兩者無明顯差別。燈盞生脈膠囊聯(lián)合常規(guī)治療未明顯增加不良反應發(fā)生。
[Abstract]:Objective to systematically evaluate the clinical efficacy and secondary preventive effect of Dengzhan Shengmai capsule in the treatment of ischemic stroke. Methods the time limit of computer retrieval of Pubmed,EMbase,Cochrane Library and CNKI,CBM,VIP,Wanfang Data, was from the construction of database to February 2016. At the same time, related magazines and web pages were searched manually for Google academic search. A randomized controlled trial on the treatment of ischemic stroke with Dengzhan Shengmai capsule was included. Two researchers independently selected the literature according to the inclusion and exclusion criteria, extracted the relevant data and evaluated the quality. Meta analysis of the outcome index was carried out by Rev Man5.3. Results A total of 18 articles and 4416 patients were included in the literature. Meta-analysis showed that compared with the control group, the experimental group could reduce the recurrence rate of stroke [RR=0.53,95%CI (0.39, 0.71). P0.000 1] and mortality [RR=0.28,95%CI (0.11, 0.68), P0.005], and clinical efficacy [RR=1.22,95%CI (1.15, 1.29), P0.000 01] and ability of daily living [MD=9.19,95%CI (3.41, 14.98), P 鈮，

本文編號：2476663